Home › Therapeutic areas › Neurology › Schizophrenia

Schizophrenia (8 companies)

Companies with an active program in Schizophrenia.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
AXSM Axsome Therapeutics Neurology Rare 1 Approved $7.15B 15
LBRX LB Pharmaceuticals Neurology 1 Phase 3 $1.30B 3
MPLT MapLight Therapeutics Neurology 1 Phase 2 $365M 3
NRXP NRX Pharmaceuticals Neurology Rare 1 Approved $109M 11
KTTA Pasithea Therapeutics NeurologyOncology Rare 1 Phase 1 $16.0M 4
RVPH Reviva Pharmaceuticals CardiovascularDermatology+3 Rare 1 Phase 3 $4.7M 11
TGTX Tg Therapeutics Neurology Rare 1 Approved $9.48B 6
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 3 Approved $230M 27